Hehlmann R - Search Results

1

Harmonization of molecular monitoring of CML therapy in Europe.

Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A. Müller MC, et al. Among authors: hehlmann r. Leukemia. 2009 Nov;23(11):1957-63. doi: 10.1038/leu.2009.168. Epub 2009 Aug 27. Leukemia. 2009. PMID: 19710700 Review.

2

Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.

Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: hehlmann r. Bone Marrow Transplant. 1996 May;17 Suppl 3:S41-4. Bone Marrow Transplant. 1996. PMID: 8769700

3

Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.

Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: hehlmann r. Leukemia. 1997 Apr;11 Suppl 3:541-4. Leukemia. 1997. PMID: 9209451

4

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.

Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A. Emig M, et al. Among authors: hehlmann r. Leukemia. 1999 Nov;13(11):1825-32. doi: 10.1038/sj.leu.2401566. Leukemia. 1999. PMID: 10557058

5

Detection and quantification of residual disease in chronic myelogenous leukemia.

Hochhaus A, Weisser A, La Rosée P, Emig M, Müller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NC. Hochhaus A, et al. Among authors: hehlmann r. Leukemia. 2000 Jun;14(6):998-1005. doi: 10.1038/sj.leu.2401811. Leukemia. 2000. PMID: 10865964 Review.

6

Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.

Saussele S, Weisser A, Müller MC, Emgi M, La Rosée P, Paschka P, Kuhn C, Willer A, Hehlmann R, Hochhaus A. Saussele S, et al. Among authors: hehlmann r. Leukemia. 2000 Nov;14(11):2006-10. doi: 10.1038/sj.leu.2401929. Leukemia. 2000. PMID: 11069038

7

Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.

Krämer A, Löffler H, Bergmann J, Hochhaus A, Hehlmann R. Krämer A, et al. Among authors: hehlmann r. Leukemia. 2001 Jan;15(1):62-8. doi: 10.1038/sj.leu.2402005. Leukemia. 2001. PMID: 11243401

8

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Merx K, et al. Among authors: hehlmann r. Leukemia. 2002 Sep;16(9):1579-83. doi: 10.1038/sj.leu.2402680. Leukemia. 2002. PMID: 12200666 Clinical Trial.

9

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Hochhaus A, et al. Among authors: hehlmann r. Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741. Leukemia. 2002. PMID: 12399961 Clinical Trial.

10

Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.

Müller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, Hochhaus A. Müller MC, et al. Among authors: hehlmann r. Leukemia. 2002 Dec;16(12):2395-9. doi: 10.1038/sj.leu.2402734. Leukemia. 2002. PMID: 12454744

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

468 results

Search Page

Filters